Table 1.
Baseline characteristics of pT3N0M0 and pT1−3N1M0 groups before and after matching, SEER 2004-2015.
| Characteristic | Before matching | After matching* | ||||
|---|---|---|---|---|---|---|
| Stage III-N0 | Stage III-N1 | P† | Stage III-N0 | Stage III-N1 | P† | |
| pT3N0M0 | pT1−3N1M0 | pT3N0M0 | pT1−3N1M0 | |||
| (N = 1554, %) | (N = 446, %) | (N = 373, %) | (N = 373, %) | |||
| Age, mean (95%CI), y | 60.2 (59.7–60.8) | 60.2 (59.1–61.3) | 0.93 | 60.1 (59.0–61.3) | 60.5 (59.3–61.7) | 0.70 |
| Sex | 0.085 | 0.34 | ||||
| Male | 1059 (68.1) | 323 (72.4) | 257 (68.9) | 269 (72.1) | ||
| Female | 495 (31.9) | 123 (27.6) | 116 (31.1) | 104 (27.9) | ||
| Race | <0.001 | 0.14 | ||||
| White | 1354 (87.1) | 359 (80.5) | 319 (85.5) | 304 (81.5) | ||
| Non-white | 200 (12.9) | 87 (19.5) | 54 (14.5) | 69 (18.5) | ||
| Grade | <0.001 | 1.0 | ||||
| Well/moderately | 442 (28.4) | 81 (18.2) | 74 (19.8) | 74 (19.8) | ||
| Poor | 705 (45.4) | 224 (50.2) | 164 (44.0) | 164 (44.0) | ||
| Undifferentiated | 275 (17.7) | 102 (22.9) | 96 (25.7) | 96 (25.7) | ||
| Unknown | 132 (8.5) | 39 (8.7) | 39 (10.5) | 39 (10.5) | ||
| Tumor site | 0.56 | 0.66 | ||||
| Left | 885 (56.9) | 247 (55.4) | 207 (55.5) | 201 (53.9) | ||
| Right | 669 (43.1) | 199 (44.6) | 166 (44.5) | 172 (46.1) | ||
| Histology | <0.001 | 1.0 | ||||
| Clear cell | 1407 (90.5) | 286 (64.1) | 286 (76.7) | 286 (76.7) | ||
| Chrompohobe | 80 (5.1) | 21 (4.7) | 21 (5.6) | 21 (5.6) | ||
| Papillary | 67 (4.3) | 139 (31.2) | 66 (17.7) | 66 (17.7) | ||
| T stage | NA | NA | ||||
| T1 | 0 (0) | 61 (13.6) | 0 (0) | 48 (12.9) | ||
| T2 | 0 (0) | 91 (18.2) | 0 (0) | 70 (18.8) | ||
| T3a | 934 (60.1) | 216 (48.4) | 234 (62.7) | 176 (47.2) | ||
| T3b | 527 (33.9) | 71 (15.9) | 123 (33.0) | 65 (17.4) | ||
| T3c | 60 (3.9) | 10 (2.2) | 13 (3.5) | 8 (2.1) | ||
| T3NOS | 33 (2.1) | 7 (1.6) | 3 (0.8) | 6 (1.6) | ||
| N stage | NA | NA | ||||
| N0 | 1554 (100.0) | 0 (0.0) | 373 (100.0) | 0 (0.0) | ||
| N1 | 0 (0.0) | 446 (100.0) | 0 (0.0) | 373 (100.0) | ||
| Invasion beyond capsule‡ | NA | NA | ||||
| No | 426 (38.3) | 148 (50.0) | 92 (33.0) | 121 (50.0) | ||
| Yes | 600 (53.9) | 122 (41.2) | 165 (59.1) | 102 (42.1) | ||
| Unknown | 87 (7.8) | 26 (8.8) | 22 (7.9) | 19 (7.9) | ||
| Fuhrman nuclear grade‡ | NA | NA | ||||
| Grade 1/2 | 330 (29.6) | 37 (12.5) | 67 (24.0) | 34 (14.0) | ||
| Grade 3 | 489 (43.9) | 143 (48.3) | 114 (40.9) | 99 (40.9) | ||
| Grade 4 | 217 (19.5) | 84 (28.4) | 76 (27.2) | 81 (33.5) | ||
| Unknown | 77 (6.9) | 32 (10.8) | 22 (7.9) | 28 (11.6) | ||
| Sarcomatoid features‡ | NA | NA | ||||
| Absence | 1016 (91.3) | 248 (83.8) | 247 (88.5) | 200 (82.6) | ||
| Presence | 62 (5.6) | 37 (12.5) | 25 (9.0) | 35 (14.5) | ||
| Unknown | 35 (3.1) | 11 (3.7) | 7 (2.5) | 7 (2.9) | ||
| LNs examined, mean (95%CI) | 9 (8–10) | 9 (7–11) | 0.96 | 10 (8–12) | 9 (7–11) | 0.30 |
| LNs positive, mean (95%CI) | 0 (0–0) | 6 (4–8) | NA | 0 (0–0) | 6 (4–8) | NA |
LN, lymph node; CI, Confidence interval; NA, Not applicable.
*
Adjusted for group, age, grade, and histology.
†
Derived from χ2-test for categorical variables, general linear models for continuous variables.
‡
Invasion beyond capsule, fuhrman nuclear grade, and sarcomatoid features were only applicable for 2010+ cases, and not enter into the χ2-test, thus the P-value was not applicable.